Skip to main content

Table 2 Pareto classification of health change classification of changes from baseline in EQ-5D dimensions

From: Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

  Enzalutamide (n = 872), n (%) Placebo (n = 845), n (%) P value
Week 13 n = 783 (89.8%) n = 605 (71.6%)  
Worsening 208 (26.6%) 230 (38.0%) <0.0001
No change 337 (43.0%) 242 (40.0%)  
Improvement 190 (24.3%) 94 (15.5%) <0.0001
Mixed change 48 (6.1%) 39 (6.5%)  
Week 25 n = 726 (83.3%) n = 356 (42.1%)  
Worsening 194 (26.7%) 123 (34.6%) 0.0078
No change 288 (39.7%) 151 (42.4%)  
Improvement 193 (26.6%) 64 (18.0%) 0.0018
Mixed change 51 (7.0%) 18 (5.1%)  
Week 37 n = 649 (74.4%) n = 258 (30.5%)  
Worsening 198 (30.5%) 95 (36.8%) 0.0666
No change 252 (38.8%) 100 (38.8%)  
Improvement 146 (22.5%) 43 (16.7%) 0.0512
Mixed change 53 (8.2%) 20 (7.8%)  
Week 49 n = 594 (68.1%) n = 168 (19.9%)  
Worsening 210 (35.4%) 61 (36.3%) 0.8192
No change 214 (36.0%) 74 (44.1%)  
Improvement 132 (22.2%) 22 (13.1%) 0.0093
Mixed change 38 (6.4%) 11 (6.6%)  
Week 61 n = 507 (58.1%) n = 113 (13.4%)  
Worsening 193 (38.1%) 51 (45.1%) 0.1644
No change 180 (35.5%) 41 (36.3%)  
Improvement 101 (19.9%) 18 (15.9%) 0.3299
Mixed change 33 (6.5%) 3 (2.7%)